ES2607794T3 - Compuestos heterocíclicos novedosos y usos de los mismos - Google Patents

Compuestos heterocíclicos novedosos y usos de los mismos Download PDF

Info

Publication number
ES2607794T3
ES2607794T3 ES08768240.7T ES08768240T ES2607794T3 ES 2607794 T3 ES2607794 T3 ES 2607794T3 ES 08768240 T ES08768240 T ES 08768240T ES 2607794 T3 ES2607794 T3 ES 2607794T3
Authority
ES
Spain
Prior art keywords
compound
formula
free
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08768240.7T
Other languages
English (en)
Spanish (es)
Inventor
Peng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Application granted granted Critical
Publication of ES2607794T3 publication Critical patent/ES2607794T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES08768240.7T 2007-06-07 2008-06-06 Compuestos heterocíclicos novedosos y usos de los mismos Active ES2607794T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93378207P 2007-06-07 2007-06-07
US933782P 2007-06-07
PCT/US2008/007167 WO2008153974A1 (en) 2007-06-07 2008-06-06 Novel heterocycle compounds and uses thereof

Publications (1)

Publication Number Publication Date
ES2607794T3 true ES2607794T3 (es) 2017-04-04

Family

ID=40130063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08768240.7T Active ES2607794T3 (es) 2007-06-07 2008-06-06 Compuestos heterocíclicos novedosos y usos de los mismos

Country Status (5)

Country Link
US (2) US9062023B2 (enExample)
EP (1) EP2166860B1 (enExample)
JP (2) JP5559043B2 (enExample)
ES (1) ES2607794T3 (enExample)
WO (1) WO2008153974A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469810A4 (en) 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
WO2008153974A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
CN107652269A (zh) * 2016-07-26 2018-02-02 江苏豪森药业集团有限公司 甲磺酸氟马替尼中间体纯化方法
JP2022523562A (ja) * 2019-03-05 2022-04-25 ホンイー アンド アソシエイツ エルエルシー 神経変性疾患および癌の治療のための化合物
CN116789643B (zh) * 2023-06-25 2025-05-06 海南医学院 一种2-氨基嘧啶类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP2308833A3 (en) * 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1469810A4 (en) 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
RU2315043C2 (ru) 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
CN1805748B (zh) 2003-06-13 2010-05-26 诺瓦提斯公司 作为raf激酶抑制剂的2-氨基嘧啶衍生物
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE602005023587D1 (de) 2004-01-21 2010-10-28 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
CA2578122A1 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
WO2008153974A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
US8367686B2 (en) * 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
HUE027027T2 (en) * 2008-11-13 2016-08-29 Modgene Llc Reduction of amyloid beta load in non-brain tissue

Also Published As

Publication number Publication date
JP5559043B2 (ja) 2014-07-23
WO2008153974A1 (en) 2008-12-18
US20160075683A1 (en) 2016-03-17
JP2010529132A (ja) 2010-08-26
JP6017496B2 (ja) 2016-11-02
EP2166860A1 (en) 2010-03-31
EP2166860A4 (en) 2010-06-02
JP2014193912A (ja) 2014-10-09
US20100184778A1 (en) 2010-07-22
US9062023B2 (en) 2015-06-23
EP2166860B1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
ES2607794T3 (es) Compuestos heterocíclicos novedosos y usos de los mismos
JP6629947B2 (ja) 高インスリン血症に関連した症状の処置
JP5710251B2 (ja) 新規ヘテロ環化合物およびその使用
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
BR0109469A (pt) Compostos derivados de b-aminoácidos, composição farmacêutica, método para o tratamento ou prevenção de disfunções inflamatórias, método para o tratamento de condições ou doenças mediadas por mmps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso do composto
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
KR20160038008A (ko) 브로모도메인 억제제로서 신규 퀴나졸리논
EP2597087A1 (en) Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
CY1112601T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης
MXPA04000905A (es) Derivados de amino-ftalazinona activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
CA3187432A1 (en) Compounds and methods for blocking apoptosis and inducing autophagy
ES2396764B1 (es) FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
HUP0201024A2 (hu) Izoindoloindolon-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
MX2023005071A (es) Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas.
CN114989079A (zh) Ripk1激酶靶点抑制剂及其医药用途
US10632127B2 (en) Targeted notch pathway inhibitors
MX2025009690A (es) Antagonistas de receptores opioides kappa.
NZ760036A (en) Dihydro-pyrrolo-pyridine derivatives
TH76965A (th) สารยับยั้งเอนไซม์ เคซีน ไคเนส ไอเอปซิลอน ชนิด 5- และ 6-อะมิโนอัลคิล อินโดล-2-กรดคาร์บอกซิลิค เอไมด์ ที่มีหมู่แทนที่ที่ตำแหน่ง 3 และอนาล็อกที่เทียบเคียงกัน
JPWO1997045410A1 (ja) 神経細胞保護剤